Navigation Links
How molecules out of balance lead to human multiple myeloma and other cancers
Date:7/29/2008

An international team of scientists has identified processes that are heavily implicated in human multiple myeloma and other B cell cancers, moving us closer to developing quick tests and readouts that could help in the tailored treatment of patients.

B cells, the white blood cells that produce antibodies, form a key part of our 'immune response'. To remain healthy, we need to maintain the right number of B cells, not too many and not too few. This in turn relies on an intricate interplay of molecules within our bodies, and inside our B cells.

Professor Fabienne Mackay, Professor Klaus Rajewsky and Dr Marc Schmidt-Supprian, from Sydney's Garvan Institute of Medical Research, Harvard Medical School and Germany's Max Planck Institute of Biochemistry respectively, have identified two processes that appear to influence B cell driven cancers. Their findings are published online this week in the international journal Proceedings of the National Academy of Sciences (US).

"We already know that the over-expression or mutation of molecules known as NIK and TRAF3 in B cells is associated with human multiple myeloma," said Professor Mackay. "Our collaborative research uncovered two distinct processes involving these molecules that help explain why."

The first process involves NIK, an enzyme that acts closely with BAFF, the substance that regulates the number of B cells in our bodies. Work done previously by Professor Mackay on BAFF showed that levels correlate with B cell hyperplasia (expansion) and cancer. The current study shows that if we have too much NIK in our systems, then our B cells will also expand, and we will be prone to cancer.

The second process, associated with the first, involves TRAF3, the molecule that negatively regulates NIK.

Professor Mackay explained that in a healthy person, NIK and TRAF3 work together, helping to maintain the right number of B cells for survival. "But when there are mutations in either molecule, they become uncoupled. In other words, TRAF 3 no longer represses the action of NIK when necessary."

"The important thing to note is that when you uncouple NIK from TRAF3 action, its levels are not necessarily going to go up, but its function is going to be changed. This can lead to B cell hyperplasia and cancer."

"Our paper is saying 'be careful'! Sometimes you can find a patient without high expression of NIK, so you think NIK is not implicated, where it might be."

"In the very near future, we will have the capacity to do blood tests and test for specific gene mutations in patients. Once you identify a mutation, you can bypass the action of that gene, with targeted medications."

"Both NIK and TRAF3 are molecules, so can potentially be targeted by pharmaceuticals. We anticipate that new treatments for cancers may emerge from our findings."


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Research Australia
Source:Eurekalert

Related medicine news :

1. New class of RNA molecules may be important in human cancer
2. Study Describes Molecules That Control Blood Pressure
3. Researchers identify molecules with interesting anti-clotting properties
4. Major Advance in the Observation of DNA Molecules
5. Molecules can block breast cancers ability to spread
6. Tiny RNA Molecules Control Breast Cancers Spread
7. Molecules might identify high-risk acute-leukemia patients
8. Molecules may help predict survival in liver cancer
9. Novel molecules developed at UB can boost vaccine potency
10. New understanding of how big molecules bind will lead to better drugs, synthetic organic materials
11. Allergic response tied to lipid molecules in cell membrane
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... ... Schneider Insurance and Financial, a southern Montana firm providing asset protection and financial ... a charity event aimed at raising local support for Zoo Montana. , Zoo Montana ... home to a broad variety of animals from all over the world. Many of ...
(Date:3/22/2017)... ... March 22, 2017 , ... Chris Humphrey Insurance Agency, a North ... professionals throughout the coastal plains region, is initiating a charity event to raise support ... was first diagnosed with leukemia on a Friday evening in September 2014. At the ...
(Date:3/22/2017)... Olathe, KS (PRWEB) , ... March 22, 2017 , ... ... Coach Bill Self still makes time for recruiting – that is, recruiting people to ... their hearts and homes to children who are in foster care due to abuse, ...
(Date:3/22/2017)... ... March 22, 2017 , ... HumanHaus is proud to announce the launch ... broom was great when it was invented, but our customers today are busy, energetic, ... social young couple, the empty nesters and retired that want to travel. ...
(Date:3/22/2017)... ... ... NYC Chiropractor Dr. Steven Shoshany recently helped host a seminar at his ... U.S. and focused on a new protocol for treating pain. Dr. Shoshany is among ... and furthermore the first seminar in the country was hosted at his Integrated Chiropractic ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)...  ImaginAb Inc. today announced the appointment of Martyn Coombs ... , chairman of ImaginAb, said "At ImaginAb we have exciting science ... relevant to our business, particularly in commercializing and making step changes ... we can realize our potential." ... Mr. Coombs is a recognized industry leader in nuclear ...
(Date:3/22/2017)... 2017 Research and Markets has announced ... Market & Clinical Pipeline Insight 2022" drug pipelines to ... ... Pipeline Insight 2022 report gives comprehensive insight on clinical and ... check point inhibitors as main streamline drugs in the immunotherapy ...
(Date:3/22/2017)... LINCOLN, Mass. , March 22, 2017 /PRNewswire/ ... applying mechanistic modeling to drug research and development, ... QSP Day 2017.  QSP Day 2017 is a ... with the quantitative systems pharmacology (QSP) community. The ... mathematical modeling is de-risking and accelerating drug research ...
Breaking Medicine Technology: